Finding the right molecule in a haystack of life-saving possibilities

Developing a new drug starts with identifying the molecule or "ligand" that can block the molecular target or "receptor" involved in a disease. Even with high throughput screening, finding that one functional ligand for a receptor from a haystack of millions of possible compounds is expensive, high–risk and time–consuming. Converting a promising target into a commercial drug typically takes about 15 years and costs up to $800 million. To accelerate the discovery process, Canadian Glycomics Network (GlycoNet), in partnership with the Alberta Glycomics Centre (AGC) and the Derda Research Group at the University of Alberta (U of A), launched a… read more >>

Bennett Jones IP and Alberta Glycomics Centre: Innovation Vanguards

Bennett Jones is pleased to announce it is now providing intellectual property services to the Alberta Glycomics Centre. The Centre is home to some of the world’s most accomplished experts in carbohydrate-based research and is located at the University of Alberta. The focus of the Centre’s research is understanding the interactions of carbohydrates at the molecular level and applying the knowledge toward medical and commercial uses. These include projects designed to develop vaccines against tuberculosis, bloodstream infections in hospitalized patients, various cancers and Alzheimer’s disease. “The Alberta Glycomics Centre has been a leader in innovation and commercialization in Alberta and… read more >>

Article accepted for publication in Journal of Food Engineering

AGC Core Services manager Daniel Hernandez Armada has co-authored a paper on "Enzymatic conversion of lactose into galacto-oligosaccharides" that has been accepted for publication in the Journal of Food Engineering. Click here for PDF version.

European patent granted

Pleased to report that the European Patent Office (EPO) has issued a decision to grant a European patent pursuant to Article 97(1) EPC to our technology titled "Methods and Systems for O-Glycosylating Proteins." Another successful development in our IP portfolio. Congratulations to all involved with developing and guiding this technology through the patent process.

Chemical biologist uses sugars in the body to unlock biological questions.

A field at the forefront of biomedical science, glycosciences is the study of complex roles for carbohydrates--also described as oligosaccharides or glycans--in biological systems. Going far beyond a role as an energy source, carbohydrates orchestrate many critical cellular processes, all the way from fertilization to programmed cell death. Click here for full article. Published originally by U of A Faculty of Science on November 2, 2017

Three vacancies in Klassen group lab team

The Klassen group currently has vacancies for two PhD and one post-doctoral specialists in biomolecular mass spectrometry and functional glycomics. For more information on these positions please contact Dr. John Klassen.

Macauley Lab website launched

The website for the Macauley Lab has gone live today. Click here to visit for information on current research, publications, as well as collaboration and employment opportunities.

Edmonton startup wants to put Alberta at epicentre of molecular discoveries (Edmonton Journal)

"A University of Alberta biotechnology spinoff wants to put Edmonton at the epicentre of molecular discoveries by creating an immense searchable database that could speed up and drive down the cost of research and development." Click here for the full article in the Edmonton Journal.

Launch of AGC-supported spin-off company

The Alberta Glycomics Centre is proud to support the launch of biotech spin-off company 48Hour Discovery Inc., an Alberta-based company providing services in ligand discovery in unprecedented turnaround time and within a fully manageable costing model. Founded in February 2017, 48HD's core business is rooted in a proprietary molecular discovery platform emanating from the expertise and intellectual property generated from the Derda Research Group under the AGC research and commercialization umbrella. The company provides rapid ligand discovery services for any target using its expansive portfolio of genetically-encoded molecules, mining technology, and a standardized discovery protocol. More to follow on this… read more >>

Dr. John Klassen article in Analytical Chemistry

AGC Director Dr. John Klassen's co-authored article "Investigating the Influence of Membrane Composition on Protein-Glycolipid Binding Using Nanodiscs and Proxy Ligand ESI-MS" has been accepted for publication in Analytical Chemistry. Watch this site for updates and links.